

16/784916

SEARLE

Patent Department

G.D.Searle & Company
c/o Monsanto Company
800 North Lindbergh Boulevard
St. Louis, Missouri 63167

Telephone: (314) 694-9092
FAX: (314) 694-9095

FACSIMILE COVER SHEET

*Parent
from Application # 08/110,912*

DATE:

August 5, 1994

TO:

Examiner J. Conrad
Art Unit 1204

COMPANY:

United States Patent & Trademark Office

FAX NUMBER:

703-308-4556

FROM:

FRANK UNGEMACH
PATENT ATTORNEY

TOTAL NUMBER OF PAGES (INCLUDING COVER SHEET): 8

IF YOU DO NOT RECEIVE ALL OF THE PAGES,
PLEASE CALL (314) 694-9092.

THIS FACSIMILE MESSAGE IS **CONFIDENTIAL** AND MAY CONTAIN
PRIVILEGED INFORMATION. If you are not the intended recipient,
you are hereby notified that any use, copying or dissemination
of this material is prohibited. Please notify us at the number
listed above and destroy the original message. Thank you.

COMMENTS:

RECEIVED

AUG 8 1994

J2M 8/8/94 8/9/94

PATENT

C-2704/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

M. L. Vazquez et al.

SERIAL NUMBER: 08/110,912

FILED: August 24, 1993

TITLE: CYCLIC SULFONE
CONTAINING RETROVIRAL
PROTEASE INHIBITOR

Group Art Unit: 1204


EXAMINER: J. Conrad

DATE: August 5, 1994

#7
8/9/94
MercerInformal CommunicationThe Commissioner of Patents and Trademarks
Washington, D.C. 20231


Dear Sir:

This communication confirms the Election of Species for the above-identified patent application communicated to the Examiner by telephone on August 4, 1994. The elected species has the following chemical structure:




otherwise known as [1S-[1R*(S*), 2S*]]-N⁴-[2-hydroxy-3-[(2-methylpropyl)(4-methoxyphenylsulfonyl)amino-1-(phenylmethyl)propyl]-2,2,3-trimethyl-butanediamide, which is disclosed in Applicants' specification in Table 9, entry #6, page 66 and is claimed in Claim 173, page 98, lines 6-8.


As requested, the following is the chemical structures corresponding to the claimed compounds in Claim 173:




Butanediamide, N⁴-[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo, phenylmethyl ester, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]-




Butanediamide, N⁴-[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo, phenylmethyl ester, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]-




Butanediamide, N⁴-[2-hydroxy-3-[(3-methylbutyl)(4-methoxyphenylsulfonyl)amine]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(4-methoxyphenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo, phenylmethyl ester, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(4-methoxyphenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]




Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo, phenylmethyl ester, [1S-[1R*(S*),2S*]]-




Butanediamide, N⁴-[2-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, [1S-[1R*(S*),2S*]]



Butanediamide, N⁴-[2-hydroxy-3-[(3-methylbutyl)(4-fluorophenylsulfonyl)amine]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, [1S-[1R*(S*),2S*]]-




Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(4-fluorophenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo, phenylmethyl ester, [1S-[1R*(S*),2S*]]-



Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(4-fluorophenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]-

Please let me know if I may be of further assistance.

Respectfully submitted,



Frank S. Ungemach
Attorney for Applicants
Registration No. 34,449
314-694-9092 (St. Louis)

G. D. Searle & Co.
Corporate Patent Department
P.O. Box 5110
Chicago, Illinois 60680-9889